Grace Wright, MD, PhD

In "The Next Five Years in Psoriasis: Remission, Access, and Combinations," the panel looks ahead to the advances and the unfinished work of the coming years.

"The Patient Who Is Better but Not Clear: Shared Decisions in Psoriasis" takes up the common scenario of a patient content with partial improvement.

In "Putting On-Treatment Remission Into Practice: A Patient-Defined Target in Psoriasis," the panel returns to remission and grounds it in what patients actually live with.

In "Real-World Evidence and Systemic Inflammation in Psoriasis," our experts scrutinize the evidence behind popular claims about disease progression.

This episode, "IL-17 Inhibitor Safety in Psoriasis: Candidiasis, IBD, and Mental Health," features the panel putting the class's safety signals in context.

In "BE BOLD Head-to-Head: IL-17 vs IL-23 for Psoriasis and PsA," the panel digs into the trial that broke the usual non-inferiority pattern.

"Exploring the IL-17 vs IL-23 Debate in Psoriasis " takes up a deliberately provocative question from the moderator.

In "IL-17 vs IL-23: Head-to-Head Data in Psoriasis and PsA," our experts turn to the trials clinicians actually reach for when choosing a class.

This episode, "Targeting the Pathways: TNF, IL-17, and IL-23 in Psoriasis," features the panel unpacking the biology behind today's biologics.

In "Defining On-Treatment Remission in Psoriasis and PsA," the panel examines whether clear should now mean completely clear.

"Breaking Down Silos: Rheum-Derm Collaboration in Psoriasis Care" takes up the question of how two specialties can stop working in isolation.

Most psoriatic arthritis is preceded by psoriasis, which puts dermatologists on the front line of early detection. The panel details which patients warrant a closer look and how to screen efficiently.

Plaque psoriasis has reached total clearance for many patients, yet psoriatic arthritis still lags behind. The panel opens by mapping where the two halves of psoriatic disease diverge.